CD14 and Behcet disease: The IL-12 increase was significantly lower in the treated groups compared to the BD group: Coversin group 2126 pg/mL (1526–2706) (p = 0.0003), anti-CD14 group 2422 pg/mL (1119–3725) (p = 0.001) and the dual treatment group 2658 pg/mL (1430–3885) (p = 0.003) (Fig. 1C).